

**UCSF**

**UC San Francisco Previously Published Works**

**Title**

Structural neuroimaging in polysubstance users

**Permalink**

<https://escholarship.org/uc/item/4j5202m1>

**Author**

Meyerhoff, Dieter J

**Publication Date**

2017-02-01

**DOI**

10.1016/j.cobeha.2016.07.006

Peer reviewed



# HHS Public Access

Author manuscript

*Curr Opin Behav Sci.* Author manuscript; available in PMC 2018 February 01.

Published in final edited form as:

*Curr Opin Behav Sci.* 2017 February ; 13: 13–18. doi:10.1016/j.cobeha.2016.07.006.

## Structural Neuroimaging in Polysubstance Users

**Dieter J. Meyerhoff, Dr.rer.nat.**

Department of Radiology and Biomedical Imaging, University of California San Francisco, and Veterans Administration Medical Center, San Francisco, CA 94121, USA

### Abstract

The simultaneous and/or concurrent use of licit and illicit substances (polysubstance use, PSU) is most common today. Structural magnetic resonance imaging (MRI) has been applied extensively to study individuals ostensibly using a single substance. These studies have produced a picture of regional gray matter and white matter alterations with each substance or class of substances. Very few studies measured regional brain morphometry in today's polysubstance users. This limited data suggest morphometric alterations with PSU that are not simply additive but often different from those of monosubstance users. Specifically, subcortical volume enlargements are observed that may be tied to mechanisms that also oppose volume reductions in cortical brain regions, thereby underestimating actual cortical atrophy. The complex actions of polysubstance use on brain structure and function need greater scrutiny with strong methodological approaches to inform more efficient treatment of polysubstance users.

### Introduction

Polysubstance use (PSU), the simultaneous or concurrent use of two or more psychoactive substances has become the most common form of chronic substance use today in the developed world. Most alcohol dependent individuals are also chronic consumers of tobacco products, many cocaine and/or amphetamine dependent individuals also smoke cigarettes and consume alcohol regularly, and many of these substance users also smoke marijuana (cannabis) [1–3]. Monosubstance use appears to be a thing of the past, except perhaps for nicotine dependence and when substance use is first initiated. This is reflected in the changing profile of the clientele at substance abuse treatment centers in the developed world, where the majority of individuals with alcohol use disorders, for example, also chronically misuse illicit drugs.

Research aimed at understanding the effects and correlates of substance use on the brain has traditionally focused on studying the substance of interest by excluding or minimizing the concurrent use of other substances. While this valid scientific approach has provided

---

Postal address: Dr. Dieter J. Meyerhoff, VA Medical Center, 4150 Clement St. #114M, San Francisco, CA 94121, TEL 415-221-4810 x2-4803, dieter.meyerhoff@ucsf.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The author has no financial or any other personal conflicts with this work.

invaluable insights into the neural correlates of individual substances misused, it also raises questions about generalizability: How relevant are these findings to today's substance users? Can these insights inform properly on brain changes related to PSU so that they can intelligently inform the design and development of effective treatment for PSU?

The current knowledge of brain structural alterations in polysubstance users is very limited, and we dare say that this contributes not only to a lack of understanding of the functional ramifications of such alterations, but more importantly also to the lack of effective treatment and the lack of guidance for clinical management of the majority of individuals seen in treatment today. Here, we first give a brief summary of brain structural alterations described for different classes of abused substances and then review the limited literature on brain structural alterations associated with PSU. Throughout the narrative, we highlight brain morphometric differences between mono- and polysubstance users, which we believe are reason for targeted treatment approaches based on the class of substances abused.

### Monosubstance Use Studies by Name

Brain tissue loss with concomitant cerebral spinal fluid enlargements is well established in *alcohol use disorders (AUD)* (for recent reviews see e.g., [4, 5]). Quantitative structural magnetic resonance imaging (MRI) in chronic alcohol users showed that the gray matter regions primarily reduced are the bilateral prefrontal cortices, the posterior cingulate cortex, the insula, and subcortical brain regions, including the bilateral dorsal striatum (caudate, putamen, and nucleus accumbens), the hippocampi, and the amygdala; additional periventricular white matter loss is a common finding in severe alcohol users [6]. By enlarge, these are brain regions commonly described as abnormal in the general drug addiction literature, and most belong to a neural network referred to as the brain reward/ executive oversight system (BREOS), which enables cognition, adaptive and appropriate goal-related behavior including reward and affect. Because the prefrontal brain is involved in drug-craving, impulsive/compulsive behavior and decision-making, its structural (and underlying metabolic) injury - be it as a consequence of chronic drinking and/or as a premorbid risk factor - may explain some of the difficulties encountered by substance users to achieve and maintain longterm abstinence.

Structural brain alterations are also detected in *chronic stimulant users*. A recent review [7] found fairly consistently across most imaging studies that chronic stimulant users had cortical gray matter reductions in the ventromedial prefrontal cortices (including the anterior cingulate (ACC)) and the insula. Individuals with primary cocaine dependence, but not those with methamphetamine dependence, also showed volume loss in the temporal cortices. Less consistently, gray matter volume reductions were reported in cerebellum, amygdala, and parahippocampal gyrus; in contrast to AUD, hippocampal volume was generally not reduced in stimulant dependence. Also in contrast to AUD, volume increases have been reported in the striatum of chronic psychostimulant users compared to drug-free controls [8–13].

The structural brain imaging findings in *chronic amphetamine users* are quite similar to those in chronic cocaine users, with most studies showing smaller volume in the medial frontal cortex and insula; temporal lobe volume reductions however have not been reported.

Frontal atrophy appears persistent in longterm abstinent methamphetamine users, similar to findings in cocaine dependence. The globus pallidus and putamen were enlarged in longterm abstinent methamphetamine users [12], but not in a dose-dependent manner. Substance users usually do not restrict their use to one type of stimulant; in as much as MDMA (“ecstasy”) and amphetamines (“speed”) are commonly used concurrently (amphetamine-type stimulants), often together with significant marijuana and alcohol consumption, this form of PSU in experienced users was associated with cortical thinning and/or volume loss primarily in lateral and medial prefrontal cortices [14, 15]. Similarly, when amphetamine disorder is comorbid with heavy alcohol consumption, cortical thinning in prefrontal brain regions is increased [16]. Significant medial frontal cortex and insula atrophy was not observed in occasional young stimulant users; they instead showed smaller right cerebellum and inferior parietal cortex volumes, but, similar to chronic users, they also showed larger putamen volume; furthermore, stimulant use measures in these occasional young users correlated with larger volumes of right ventromedial frontal cortex and left insula [17]. Taken together, it is unclear if the striatal volume increases seen in stimulant users constitute a premorbid risk factor for stimulant use or are a result of chronic use, potentially related to compensatory neural processes, to extracellular dopamine increases with drug use or to neuroinflammatory processes [18, 19]. It is also not known if factors that contribute to volume increases in subcortical brain regions also affect cortical morphometry, thereby potentially underestimating measured cortical injury in chronic stimulant users.

We are aware of only one truly longitudinal structural MRI study in psychostimulant users; it involved methamphetamine abusers over 5 months of abstinence [20]. In numerous serial studies of abstinent alcoholics, we and others showed substantial neurobiological, including structural and cognitive recovery with abstinence [4, 5, 21].

Recent evidence has emerged for atrophy related to both *chronic tobacco and marijuana (cannabis) use*, which are both highly comorbid with other substance use. A recent review of imaging studies in chronic smokers (who did not abuse other substances) described gray matter volume/density reductions in prefrontal, anterior cingulate, parietal, occipital, and temporal cortices, insula, striatal nuclei, thalami and the cerebellum [22]. A large voxel-based morphometry (VBM) study of MRI data from nearly 1000 current and never-smokers revealed gray matter volume loss in the prefrontal and anterior cingulate cortices, the insula, and the olfactory gyrus, with white matter volumes being not significantly affected [23]. The gray matter loss in current smokers was related positively to lifetime use of cigarettes (pack-years). In non-treatment seeking individuals with AUD, we found smaller total and temporal gray matter volumes in cigarette smokers vs. non-smokers [24], consistent with parietal and temporal gray matter atrophy in smoking vs. non-smoking treatment seeking alcoholics [25]. More pack-years in individuals in their sixth decade were associated with smaller left nucleus accumbens area volume and larger left putamen volume [26]. Larger putamen volume was also associated with a lower age at smoking initiation.

*Chronic marijuana use* by itself is related to volumetric alterations within the mesial temporal lobe (i.e., hippocampus and amygdala) and subregions of the prefrontal cortex and the cerebellum. The findings, however, were not always consistent across studies and both volume increases and decreases were reported, with some evidence of persistent alterations

in longterm abstinent marijuana users [27]. Teens who used both marijuana and alcohol had relatively normal hippocampal volumes, whereas teens who used alcohol only had smaller hippocampi [28], suggesting that alcohol-related atrophy may be offset by marijuana-related glial proliferation, a mechanism proposed for greater white matter density in marijuana users [29].

Note that the regions of gray matter volume affected by chronic tobacco and marijuana use are similar to those affected by AUD and stimulant use. Although rarely indicated in the participants section of the relevant papers (even when other comorbid substance use is listed), it is likely that most substance users involved in these ‘mono’-substance use studies were also chronic cigarette smokers and, additionally, that the majority of drug-free control participants were not chronic cigarette smokers (the prevalence of chronic smoking in non-clinical samples is generally much lower than in substance using populations). Thus, the observed structural abnormalities in these chronic substance users may be confounded by the effects of comorbid tobacco and/or marijuana use. Very few studies have tried to disentangle the effects from different substances abused, including tobacco, most likely because ‘pure’ mono-substance abusers are difficult to find, especially among chronic users. Therefore, the variability in the type and amount of substances abused, including tobacco and marijuana, across the different studies may have contributed to discrepancies in study results. As such, several of the studies cited above that ostensibly describe mono-substance users may in fact have described individuals with PSU, who have a drug of choice they may be dependent on, but more commonly than not also abuse or use other substances concurrently.

## Polysubstance Use Studies by Name

*Polysubstance use* was first addressed by MR-based structural neuroimaging more than 20 years ago by demonstrating no difference of the ventricle-to-brain ratio in relatively young polysubstance abusers compared to drug-free healthy controls [30]. This coarse structural measure, that essentially reflects the amount of brain tissue, may have foreshadowed more recent reports of cortical volume loss and concomitant subcortical volume increases described in studies of stimulant abusers. Gray matter volume loss in the prefrontal lobe in the absence of white matter loss was found in 2-week abstinent PSU who reported cocaine as their substance of choice, used cannabis regularly, alcohol moderately, while a third also used >2 grams heroin/week [31]. Polysubstance users dependent on two or more substances (mainly cocaine, alcohol, amphetamines and cannabis) compared to drug-free controls showed less gray matter volume bilaterally in the medial orbitofrontal cortex (OFC), a metric that correlated with the persistence in playing ‘bad’ cards, a measure of impaired decision making [32]. While these studies established structural abnormalities related to PSU, a few additional studies compared poly- to monosubstance users. One study compared treatment-seeking individuals with alcohol dependence alone to those with either comorbid alcohol and cocaine use disorders or comorbid alcohol and marijuana use disorders: both comorbid groups showed whole brain gray and white matter volumes similar to the group dependent on alcohol alone, despite their more severe lifetime drinking severities and additional substance use [33]. In addition, the age-related decline in gray matter volume was larger across the alcohol dependent group than the comorbid groups. The comorbid groups also had a higher prevalence of anterior white matter hyper-intensities than the group

dependent on alcohol alone [33]. When evaluating different brain regions, we found that gray matter loss was greater in the frontal lobe of treatment-seeking individuals with comorbid alcohol and cocaine dependence compared to those with alcohol dependence alone, controlling for differences in drinking severity [34, 35]. The comorbid group had similar gray matter volume reduction in the prefrontal cortex than individuals dependent on cocaine only [34, 36]). Furthermore, frontotemporal atrophy was still observed in alcohol dependent cocaine addicts who remained abstinent for 1 to 3 years [34, 36]. In a more recent study, all assessed subcortical volumes were normal in 3-month-abstinent alcoholics with a comorbid stimulant disorder (cocaine and/or methamphetamine), whereas their hippocampal, caudate, and thalamic, amygdala, and nucleus accumbens volumes were significantly larger than those of alcoholics without a stimulant disorder [37]. Similarly, Grodin et al. reported comparable prefrontal gray matter volume reductions in individuals with AUD and PSU, but subcortical volume reductions in AUD only [38], consistent with the reports of larger subcortical volumes in ‘pure’ stimulant users versus controls (see above).

These cross sectional MRI studies indicate that comorbid substance use is associated with frontal gray matter atrophy, but the studies do not suggest additive or synergistic effects from multiple concurrently abused substances. Specifically, chronic alcohol consumption in illicit substance users does not further decrease whole brain or frontal gray matter volumes, but comorbid cocaine dependence appears to be associated with greater frontal cortical atrophy than AUD. Furthermore, most studies cited above, in addition to accounting for drinking severity differences between substance using groups, also controlled for potential differences in abstinence duration, acknowledging the potential for structural changes during abstinence.

In a recent study performed at 1.5T magnetic field strength, we found gray matter reductions only in the temporal lobe, thalami and lenticular nuclei of 1-month-abstinent individuals with PSU (alcohol dependent individuals with at least one psychostimulant disorder, mostly cocaine and methamphetamine, with and without marijuana and tobacco use disorder) [39]. This was surprising, because 1-month-abstinent alcohol dependent individuals with similar lifetime alcohol and cigarette smoking histories did have widespread lobar gray matter atrophy. Compared to normal lobar white matter volumes in the ‘pure’ alcoholics, the PSU individuals had *larger* lobar white matter volumes than both controls and alcoholics, and the parietal white matter volume correlated positively with cocaine use in the prior year [39], suggesting a drug-related white matter expansion also reported in methamphetamine dependence [40], chronic cigarette smoking [25], and heavy marijuana use [29]. These observations are consistent with and reminiscent of the potential effects of neuroinflammation associated with stimulant use described above for the striatum or of glial proliferation described in marijuana users. As such, gliosis may mask and thereby underestimate regional gray matter atrophy in alcohol dependent individuals with comorbid illicit substance use [7].

In a similar PSU cohort examined at 4T, we were able to examine regional gray matter morphometry with finer volumetric parcellation. Regional volumes, surface areas, and cortical thickness were obtained for dorsal prefrontal cortex (PFC), ACC, OFC, and insula [41]. While the PSU group had smaller left OFC and right dorsal PFC volumes and surface

areas than controls, they did not differ significantly from 'pure' alcoholics on these measures; instead, they had thinner right ACC and left dorsal PFC. These morphometric abnormalities in subregions of the frontal lobe of PSU individuals correlated with poorer cognitive efficiency, executive function, intelligence, processing speed, higher self-reported impulsivity, and risk-taking. Chronic cigarette smoking in the PSU group was associated with trends to thinner cortices in dorsolateral PFC and OFC, consistent with significant smoking-related thinning observed in both alcoholics and controls [42]. Smoking PSU individuals also had greater age-related volume losses in parietal gray and white matter than their non-smoking counterparts, consistent with findings in AUD [25].

## Conclusions and Future Studies

Taken together, the rather small body of brain structural studies in PSU suggests both regional gray matter atrophy and regional tissue volume expansion in individuals with PSU. However, gray matter loss from concurrent use of multiple substances is not additive or synergistic. Mechanisms of cortical gray matter loss may include oxidative stress, mitochondrial degradation, vasoconstriction, neuroinflammation, and glutamate-mediated excitotoxicity, while volume expansion may be related to widespread altered glial function or myelination and neuroinflammation. By contrast, individuals with AUD, who have lifetime drinking and smoking histories similar PSU individuals, have somewhat more widespread cerebral atrophy but no regions of tissue expansion.

Any structural brain alterations (both volume reductions and subcortical enlargements) are either the result of substance use and/or they could predate substance use in a population at-risk (see e.g., [9]). Longitudinal and familial risk studies can distinguish between these possibilities. However, they are almost non-existent in stimulant users and PSU (except for [9] and references cited therein), likely because of challenges with recruitment and retention of this difficult-to-study population.

It has been shown that volume, surface areas, and cortical thickness of various top-down regions in AUD affect the ability to control future alcohol consumption [43] and that these measures are differentially sensitive to relapse and post-treatment alcohol use [44, 45]. In contrast to our AUD cohort, our PSU individuals, who relapsed within 6 to 12 months after structural MRI, compared to those who stayed abstinent, had *thicker* ACC and OFC at one month of abstinence (unpublished); these thicker cortices may reflect increased glial volume and/or neuroinflammation specific to PSU and future relapse or more active use of ACC/OFC function. Studies are useful to identify future relapsers and predict relapse based on neurobiological biomarkers.

To the best of our knowledge, no published reports in PSU addressed the question of structural recovery with abstinence. From the cross-sectional 4T PSU sample described above, we re-studied 20 PSU individuals who remained abstinent for 3 months after their baseline assessment: Preliminary evidence indicates some widespread volumetric changes in cortical and subcortical structures, as opposed to widespread volume increases commonly reported in abstinent AUD (e.g., [21, 46]). The volume changes in PSU were significant for left caudate (increase) and right superior temporal lobe (decrease). These structural changes

may underlie the significant cognitive improvements measured in these PSU individuals during abstinence, including in the clinically relevant domains of executive function, working memory, and cognitive efficiency [47]. The demonstration that the brain recovers after chronic polysubstance use by effectively engaging neuroplasticity suggests a critical window of opportunity for intervention with plasticity-based cognitive remediation methods. The corresponding improvement of function and overall brain health will likely promote long term abstinence in PSU individuals, and future studies should clarify the behavioral correlates of improved neurobiology and overall health with abstinence from PSU.

## Acknowledgments

This work was supported by the National Institutes of Health [AA10788, DA025202 and DA039903] and by services provided by the Northern California Institute for Research and Education at the San Francisco Veterans Administration Medical Center and by the use of resources and facilities at the San Francisco VA Medical Center.

## References and recommended reading

Papers are highlighted as of \*special interest and \*\*outstanding interest.

1. Moss HB, Goldstein RB, Chen CM, Yi HY. Patterns of use of other drugs among those with alcohol dependence: Associations with drinking behavior and psychopathology. *Addict Behav.* 2015; 50:192–198. [PubMed: 26151585]
2. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. *Curr Opin Psychiatry.* 2014; 27:269–275. [PubMed: 24852056] \*\* This short review examines recent polysubstance use research highlighting themes and challenges associated with studying complex patient populations with the aim to maximize the efficacy of prevention and treatment.
3. Morley KI, Lynskey MT, Moran P, Borschmann R, Winstock AR. Polysubstance use, mental health and high-risk behaviours: Results from the 2012 Global Drug Survey. *Drug Alcohol Rev.* 2015; 34:427–437. [PubMed: 25867685]
4. B. hler M, Mann K. Alcohol and the human brain: a systematic review of different neuroimaging methods. *Alcohol Clin Exp Res.* 2011; 35:1771–1793. [PubMed: 21777260]
5. Xiao P, Dai Z, Zhong J, Zhu Y, Shi H, Pan P. Regional gray matter deficits in alcohol dependence: A meta-analysis of voxel-based morphometry studies. *Drug Alcohol Depend.* 2015; 153:22–28. [PubMed: 26072220] \*\* Meta-analysis of voxel-based MRI morphometry studies in approx. 300 alcohol dependent patients versus 350 healthy controls. Consistent across studies was gray matter loss in alcohol dependence in the prefrontal cortex (including the anterior cingulate cortex), the dorsal striatum/insula, and the posterior cingulate cortex.
6. Monnig MA, Tonigan JS, Yeo RA, Thoma RJ, McCrady BS. White matter volume in alcohol use disorders: a meta-analysis. *Addict Biol.* 2013; 18:581–592. [PubMed: 22458455]
7. Mackey S, Paulus M. Are there volumetric brain differences associated with the use of cocaine and amphetamine-type stimulants? *Neurosci Biobehav Rev.* 2013; 37:300–316. [PubMed: 23253945]
8. Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH. Quantitative morphology of the caudate and putamen in patients with cocaine dependence. *Am J Psychiatry.* 2001; 158:486–489. [PubMed: 11229995]
9. Ersche KD, Jones PS, Williams GB, Smith DG, Bullmore ET, Robbins TW. Distinctive personality traits and neural correlates associated with stimulant drug use versus familial risk of stimulant dependence. *Biol Psychiatry.* 2013; 74:137–144. [PubMed: 23273722] \*\* This unique study included cocaine dependent users and their non-dependent siblings, some of whom were recreational cocaine users. Abnormal OFC and parahippocampal volumes were shared by all cocaine users, whereas limbic-striatal enlargement was shared by stimulant-dependent individuals and their non-dependent siblings. Thus, subcortical volume enlargements in cocaine users may be premonitory.



10. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, Heaton RK, Ellis RJ, Grant I. Effects of methamphetamine dependence and HIV infection on cerebral morphology. *Am J Psychiatry*. 2005; 162:1461–1472. [PubMed: 16055767]
11. Barros-Loscertales A, Garavan H, Bustamante JC, Ventura-Campos N, Llopis JJ, Belloch V, Parcet MA, Avila C. Reduced striatal volume in cocaine-dependent patients. *Neuroimage*. 2011; 56:1021–1026. [PubMed: 21338692]
12. Chang L, Cloak C, Patterson K, Grob C, Miller EN, Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. *Biol Psychiatry*. 2005; 57:967–974. [PubMed: 15860336]
13. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. *Addiction*. 2007; 102(Suppl 1):16–32. [PubMed: 17493050]
14. Koester P, Tittgemeyer M, Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J. Cortical thinning in amphetamine-type stimulant users. *Neuroscience*. 2012; 221:182–192. [PubMed: 22750208]
15. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim MJ, Hwang J, Haga E, Vimal RL, Lukas SE, Renshaw PF. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. *Drug Alcohol Depend*. 2003; 72:225–235. [PubMed: 14643939]
16. Lawyer G, Bjerkan PS, Hammarberg A, Jayaram-Lindstrom N, Franck J, Agartz I. Amphetamine dependence and co-morbid alcohol abuse: associations to brain cortical thickness. *BMC pharmacology*. 2010; 10:5. [PubMed: 20487539]
17. Mackey S, Stewart JL, Connolly CG, Tapert SF, Paulus MP. A voxel-based morphometry study of young occasional users of amphetamine-type stimulants and cocaine. *Drug Alcohol Depend*. 2014; 135:104–111. [PubMed: 24342420]
18. Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. *Neurotox Res*. 2013; 23:174–188. [PubMed: 22714667]
19. Kousik SM, Napier TC, Carvey PM. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. *Frontiers in pharmacology*. 2012; 3:121. [PubMed: 22754527]
20. Ernst T, Chang L. Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use. *J Neuroimmune Pharmacol*. 2008; 3:165–172. [PubMed: 18521756]
21. Durazzo TC, Meyerhoff DJ, Nixon SJ. Chronic cigarette smoking: implications for neurocognition and brain neurobiology. *Int J Environ Res Public Health*. 2010; 7:3760–3791. [PubMed: 21139859]
22. Wang C, Xu X, Qian W, Shen Z, Zhang M. Altered human brain anatomy in chronic smokers: a review of magnetic resonance imaging studies. *Neurol Sci*. 2015; 36:497–504. [PubMed: 25577510]
23. Fritz HC, Wittfeld K, Schmidt CO, Domin M, Grabe HJ, Hegenscheid K, Hosten N, Lotze M. Current smoking and reduced gray matter volume—a voxel-based morphometry study. *Neuropsychopharmacology*. 2014; 39:2594–2600. [PubMed: 24832823]
24. Durazzo TC, Cardenas VA, Studholme C, Weiner MW, Meyerhoff DJ. Non-treatment-seeking heavy drinkers: Effects of chronic cigarette smoking on brain structure. *Drug Alcohol Depend*. 2007; 87:76–82. [PubMed: 16950573]
25. Gazdzinski S, Durazzo TC, Studholme C, Song E, Banys P, Meyerhoff DJ. Quantitative brain MRI in alcohol dependence: preliminary evidence for effects of concurrent chronic cigarette smoking on regional brain volumes. *Alcohol ClinExpRes*. 2005; 29:1484–1495. \* First demonstration that volume loss in alcoholics may be partly driven by comorbid chronic cigarette smoking.
26. Das D, Cherbuin N, Anstey KJ, Sachdev PS, Eastaer S. Lifetime cigarette smoking is associated with striatal volume measures. *Addict Biol*. 2012; 17:817–825. [PubMed: 21392170]
27. Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yucel M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. *Curr Pharm Des*. 2014; 20:2138–2167. [PubMed: 23829361] \* Very exhaustive systematic review of the morphometry literature of cannabis use, considering group comparisons, patterns of use, relation to psychopathology; mechanisms, limitations of study designs and experimental methods, complemented by relevant studies in animals.

28. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. *Neurotoxicol Teratol.* 2007; 29:141–152. [PubMed: 17169528]
29. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. *Drug Alcohol Depend.* 2005; 77:23–30. [PubMed: 15607838]
30. Liu X, Phillips RL, Resnick SM, Villemagne VL, Wong DF, Stapleton JM, London ED. Magnetic resonance imaging reveals no ventriculomegaly in polydrug abusers. *Acta Neurol Scand.* 1995; 92:83–90. [PubMed: 7572068]
31. Liu X, Matochik JA, Cadet JL, London ED. Smaller volume of prefrontal lobe in polysubstance abusers: a magnetic resonance imaging study. *Neuropsychopharmacology.* 1998; 18:243–252. [PubMed: 9509492]
32. Tanabe J, Tregellas JR, Dalwani M, Thompson L, Owens E, Crowley T, Banich M. Medial orbitofrontal cortex gray matter is reduced in abstinent substance-dependent individuals. *Biol Psychiatry.* 2009; 65:160–164. [PubMed: 18801475] \* First study demonstrating the clinical relevance of structural brain changes in polysubstance users, their impact on decision-making.
33. Bjork JM, Grant SJ, Hommer DW. Cross-sectional volumetric analysis of brain atrophy in alcohol dependence: effects of drinking history and comorbid substance use disorder. *Am J Psychiatry.* 2003; 160:2038–2045. [PubMed: 14594753] \* Early study that suggests greater white matter atrophy in polysubstance users than alcohol dependent individuals. Future studies report either no white matter atrophy or white matter tissue expansion in PSU individuals.
34. O'Neill J, Cardenas VA, Meyerhoff DJ. Separate and interactive effects of cocaine and alcohol dependence on brain structures and metabolites: quantitative MRI and proton MR spectroscopic imaging. *Addiction Biology.* 2001; 6:347–361. [PubMed: 11900613]
35. Meyerhoff DJ, Bloomer C, Salas G, Schuff N, Norman D, Weiner MW, Fein G. Cortical metabolite in abstinent cocaine and cocaine/alcohol dependent subjects: An in-vivo proton magnetic resonance spectroscopic imaging study. *Addiction Biology.* 1999; 4:405–419. [PubMed: 20575809]
36. Fein G, Di Sclafani V, Meyerhoff DJ. Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. *Drug Alcohol Depend.* 2002; 68:87–93. [PubMed: 12167554]
37. Fein G, Fein D. Subcortical volumes are reduced in short-term and long-term abstinent alcoholics but not those with a comorbid stimulant disorder. *NeuroImage Clinical.* 2013; 3:47–53. [PubMed: 24179848] \*\* Despite significant recovery from cortical gray matter loss, alcoholics have persistent volume reductions in mesial temporal lobe and striatal regions at 3 months of abstinence, which are not observed in PSU.
38. Grodin EN, Lin H, Durkee CA, Hommer DW, Momenan R. Deficits in cortical, diencephalic and midbrain gray matter in alcoholism measured by VBM: Effects of co-morbid substance abuse. *NeuroImage Clinical.* 2013; 2:469–476. [PubMed: 24179800] \*\* The study shows patterns of brain volume alterations in polysubstance users and "pure" alcoholics that are quite consistent with an emerging consensus in the polysubstance use literature of gray matter atrophy not observed in subcortical regions.
39. Mon A, Durazzo TC, Abe C, Gazdzinski S, Pennington D, Schmidt T, Meyerhoff DJ. Structural brain differences in alcohol-dependent individuals with and without comorbid substance dependence. *Drug and alcohol dependence.* 2014; 144:170–177. [PubMed: 25263262] \*\* 1-month-abstinent PSU have less widespread cortical atrophy and larger lobar white matter volumes than 1-month-abstinent alcoholics with similar alcohol and smoking lifetime histories.
40. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED. Structural abnormalities in the brains of human subjects who use methamphetamine. *J Neurosci.* 2004; 24:6028–6036. [PubMed: 15229250]
41. Pennington DL, Durazzo TC, Schmidt TP, Abe C, Mon A, Meyerhoff DJ. Alcohol use disorder with and without stimulant use: brain morphometry and its associations with cigarette smoking, cognition, and inhibitory control. *PLoS One.* 2015; 10:e0122505. [PubMed: 25803861] \*\* PSU individuals have thinner cortices than AUD in ACC and DLPFC that correlated with cognitive dysfunction. Some regional cortical thinning was compounded in smoking PSU.

42. Durazzo TC, Mon A, Gazdzinski S, Meyerhoff DJ. Chronic cigarette smoking in alcohol dependence: associations with cortical thickness and N-acetylaspartate levels in the extended brain reward system. *Addict Biol.* 2013; 18:379–391. [PubMed: 22070867]
43. Duka T, Trick L, Nikolaou K, Gray MA, Kempton MJ, Williams H, Williams SC, Critchley HD, Stephens DN. Unique brain areas associated with abstinence control are damaged in multiply detoxified alcoholics. *Biol Psychiatry.* 2011; 70:545–552. [PubMed: 21612768]
44. Durazzo TC, Tosun D, Buckley S, Gazdzinski S, Mon A, Fryer SL, Meyerhoff DJ. Cortical thickness, surface area, and volume of the brain reward system in alcohol dependence: relationships to relapse and extended abstinence. *Alcohol Clin Exp Res.* 2011; 35:1187–1200. [PubMed: 21410483]
45. Durazzo TC, Rothlind JC, Gazdzinski S, Meyerhoff DJ. The relationships of sociodemographic factors, medical, psychiatric, and substance-misuse co-morbidities to neurocognition in short-term abstinent alcohol-dependent individuals. *Alcohol.* 2008; 42:439–449. [PubMed: 18760713]
46. Durazzo TC, Mon A, Gazdzinski S, Yeh PH, Meyerhoff DJ. Serial longitudinal magnetic resonance imaging data indicate non-linear regional gray matter volume recovery in abstinent alcohol-dependent individuals. *Addict Biol.* 2015; 20:956–967. [PubMed: 25170881] \* First study to demonstrate non-linear volumetric gray matter volume recovery in alcohol dependent individuals, with faster recovery within the first few weeks of abstinence than in the ensuing months. These gray matter volume increases correlate with improvements in processing speed. Smoking alcoholics recover less efficiently. Some degree of gray matter atrophy is persistent in 8-month-abstinent alcoholics.
47. Schmidt TP, Pennington D, Cardoos SL, Durazzo T, Meyerhoff D. Neurocognition and Inhibitory Control in Polysubstance Use Disorders: Comparison with Alcohol Use Disorders and Changes with Abstinence. *J Clin Exp Neuropsych.* 2016 (in press).

### Highlights

- The concurrent abuse of several substances is common among substance users today
- Both alcohol and stimulant abuse are associated with cortical gray matter volume loss
- Brain tissue loss is not simply additive in concurrent abuse of multiple substances
- Gliosis in polysubstance users may offset cortical volume loss and increase subcortical volume
- Some structural abnormalities in substance users may predate chronic abuse